PLX
Protalix BioTherapeutics, Inc.Verdict
We can't put a fair value on PLX right now. We haven't analysed this company yet.
Follow PLX
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 3, 2026: no open-market purchases and 18 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
Forster Eliot
director · 2026-09-03
Award
8,500 shares
Forster Eliot
director · 2026-09-03
Award
$44K
Ben Zvi Shmuel
director · 2026-09-03
Award
8,500 shares
Ben Zvi Shmuel
director · 2026-09-03
Award
$44K
Bashan Dror
PRESIDENT AND CEO · 2026-09-03
Award
160,000 shares
Show all 18 other filingsShow fewer
Bashan Dror
PRESIDENT AND CEO · 2026-09-03
Award
$829K
Bar-Shalev Amos
director · 2026-09-03
Award
8,500 shares
Bar-Shalev Amos
director · 2026-09-03
Award
$44K
Boudes Pol F
director · 2026-09-03
Award
8,500 shares
Boudes Pol F
director · 2026-09-03
Award
$44K
Melincoff Gwen A
director · 2026-09-03
Award
8,500 shares
Melincoff Gwen A
director · 2026-09-03
Award
$44K
Elze Christian
director · 2026-09-03
Award
8,500 shares
Elze Christian
director · 2026-09-03
Award
$44K
Naos Yaron
Sr. VP & COO · 2026-09-03
Award
56,000 shares
Naos Yaron
Sr. VP & COO · 2026-09-03
Award
$290K
Schwartz Aharon
director · 2026-09-03
Award
8,500 shares
Schwartz Aharon
director · 2026-09-03
Award
$44K
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. How the Payback Price works